Xconomy: Ablexis Cuts Deal With Pfizer, Four Other Pharmas, For Antibody Drug Discovery Tool
Summary
These mice, in all the vast complexity of their live immune systems, will be able to offer a better guide to antibody discovery teams as they try to pick candidates that are likely to pass all the clinical trials required by the FDA before a drug can be sold in the U.S. Once Ablexis finishes its work on its platform, called the AlivaMab, it will deliver the mouse to all five members of its consortium at the same time, and collect the equal eight-figure license fees, Green says.While deals from the past may have given exclusive access to a single company, or divvied up the technology licenses for narrow uses against specific targets or diseases, Ablexis felt that would be counterproductive.Lebanon, NH-based Adimab has struck a series of partnerships around its ability to pump out antibody candidates with a yeast-based technology that’s designed to be faster and cheaper than existing methods.But when asked about the deal structure, Green talked about how it provides a return to his investors without having to wait around for an IPO that may never materialize, or a big ticket acquisition by a single buyer.Cary Pfeffer, a partner with Third Rock, noted in a statement that today’s deal provides a “resounding endorsement” of the Ablexis technology, and also creates a “near-term liquidity event,” in which his firm and others will be able to cash out.
Classifications
AskAI Classifications
LabelsLinked Companies
